alexa Journal of Cancer Research and Immuno-Oncology- Open Access Journals

Journal of Cancer Research and Immuno-Oncology
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Editorial Board
Editor Image

Sriram Ayyaswamy
Baylor College of Medicine
USA

Editor Image

Kai Kang
Cleveland Clinic Lerner Research Institute
USA

Editor Image

Jing Li
University of Illinois at Chicago
USA

View More
Recommended Conferences
Submit Manuscript


Submit manuscript at https://www.editorialmanager.com/medicaljournals/ or send as an e-mail attachment to the Editorial Office at [email protected]

About the Journal

Journal of Cancer Research and Immuno-Oncology is a fast-developing open access journal in the field of cancer research. It focuses on becoming one of the best peer reviewed journal in the field of cancer research. Journal of Cancer Research and Immuno-Oncology covers a broad scope for the authors to make their valuable contributions in cancer biology, tumor, radiology, metastatis, cancer immunotherapy, oncology, radiation therapy etc

This Journal provides a unique forum dedicated to scientists to express their research articles, review articles, case reports and short communications on any array of latest cancer research and Immuno-Oncology. The Journal of Cancer Research and Immuno-Oncology is a Peer Reviewed Open Access Journal supported by universally prominent Editorial Board members. Abstracts and full texts of all articles published by Journal of Cancer Research and Immuno-Oncology are freely accessible to everyone.

The journal is using Editorial Manager System for quality in review process. Editorial Manager is an online manuscript submission, review and tracking system. Review processing is performed by the editorial board members of Journal of Cancer Research and Immuno-Oncology or outside experts; approval of at least two independent reviewers followed by the editor is required for acceptance of any citable manuscript. Authors may submit manuscripts and track their progress through the system, hopefully to publication. Reviewers can download manuscripts and submit their opinions to the editor. Editors can manage the whole submission/review/revise/publish process.

Cancer Immunotherapies

Cancer Immunotherapies is the treatment that uses certain parts of the immune system to fight against diseases like cancer. It is also known as biotherapy or biologic therapy. Antibody therapies are the most successful immunotherapy as it treats wide range of cancers. Immunotherapies fall into three main groups: cellular, antibody and cytokine.

Related Journals of Cancer Immunotherapies

Immunobiology, Immunotherapy: Open Access, Immunome Research, Cancer Immunology and Immunotherapy, Journal of Immunotherapy, International Journal of Immunotherapy

Tumour Immunology

Tumour Immunology is also known as cancer immunology. It is a branch of immunology that studies interactions between the immune systems and the cancer cells. It is a growing field of research that aims to discover innovative cancer immunotherapies to treat and retard progression of the disease.

Related Journals of Tumour Immunology

Cancer Clinical Trials, Cancer Medicine & Anti Cancer Drugs, Chemotherapy: Open Access, Journal of Tumor Marker Oncology, Tumor Diagnostik und Therapie, Tumor Research

Necrosis

Necrosis is the death of most or all of the cells in an organ or tissue due to disease, injury, or failure of the blood supply. Necrosis is caused by external factors to the cell or tissue, such as infection, toxins, or trauma that result in the unregulated digestion of cell components.

Related Journals of Necrosis

Cell & Developmental Biology, Cell Science & Therapy, Tissue Science & Engineering, Cell Biology: Research & Therapy, Cell Death and Differentiation, Cell death & disease, Journal of Cell Death

Tumor Immunity

The immune response to foreign antigens consists of humoral (eg, antibodies) and cellular mechanisms. Most of the humoral responses cannot prevent tumor growth. However, effector cells, such as T cells, macrophages, and natural killer cells, have relatively effective tumoricidal abilities.

Related Journals of Tumour Immunity

Cancer Clinical Trials, Cancer Medicine & Anti Cancer Drugs, Chemotherapy: Open Access, Journal of Tumor Marker Oncology, Tumor Diagnostik und Therapie, Tumor Research

Immunotherapy or biologic therapy

Immunotherapy is the "treatment of disease by inducing, enhancing, or suppressing an immune response. It uses materials either made by the body or in a laboratory to improve, target, or restore immune system function. It is not entirely clear how immunotherapy treats cancer.

Related Journals of Immunotherapy or biologic therapy

Immunobiology, Immunotherapy: Open Access, Immunome Research, Cancer Immunology and Immunotherapy, Journal of Immunotherapy, Immunotherapy, International Journal of Immunotherapy

Metastasis

Metastasis is a type of cancer that has spread from the place where it first started to another place in the body. A tumor formed by metastatic cancer cells is called a metastatic tumor or a metastasis. The process by which cancer cells spread to other parts of the body is also called metastasis.

Related Journals of Metastatic Cancer

Cancer Research, Nature Reviews Cancer, Journal of the National Cancer Institute, Clinical Cancer Research, Cancer Cell, Cancer, International Journal of Cancer

Chemotherapies

Chemotherapy is a type of cancer treatment that uses chemical substances, especially one or more anti-cancer drugs that are given as part of a standardized chemotherapy regimen. Chemotherapy may be given with a curative intent, or it may aim to prolong life or to reduce symptoms.

Related Journals of Chemotherapies

Chemotherapy: Open Access, Antimicrobial Agents and Chemotherapy, Cancer Chemotherapy and Pharmacology, Chemotherapy, Journal of Chemotherapy, Japanese Journal of Chemotherapy, Antibiotics and chemotherapy

Cancer Radioimmunotherapy

Radioimmunotherapy (RIT) uses an antibody labelled with a radionuclide to deliver cytotoxic radiation to a target cell. In cancer therapy, an antibody with specificity for a tumor-associated antigen is used to deliver a lethal dose of radiation to the tumor cells. The ability for the antibody to specifically bind to a tumor-associated antigen increases the dose delivered to the tumor cells while decreasing the dose to normal tissues.

Related Journals of Cancer Radioimmunotherapy

Imaging and Interventional Radiology, OMICS Journal of Radiology, Radiotherapy and Oncology, Reports of Practical Oncology and Radiotherapy, Journal of Radiotherapy in Practice

Cellular Immunotherapy

Cellular Immunotherapy has the potential to be a highly targeted alternative, with low toxicity to normal tissues but a high capacity to eradicate tumor. It includes the approaches that generate cellular therapies using active immunization with cells, proteins, peptides, or nucleic acids, as well as efforts that use adoptive transfer of effector cells that directly target antigens on malignant cells.

Related Journals of Cellular Immunotherapy

Cancer Immunology and Immunotherapy, Journal of Immunotherapy, Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, Immunotherapy, International Journal of Immunotherapy, Serodiagnosis and Immunotherapy in Infectious Disease

Cancer Immunology

Cancer Immunology is also known as tumour immunology. It is a branch of immunology that studies interactions between the immune systems and the cancer cells. It is a growing field of research that aims to discover innovative cancer immunotherapies to treat and retard progression of the disease.

Related Journals of Cancer Immunology

Cancer Science, Genes Chromosomes and Cancer, Cancer Immunology and Immunotherapy, Cancer Gene Therapy, Molecular Cancer, Cancer Genetics and Cytogenetics

Tumour Immunity

The involvement of the immune system in the host response to tumors is complex and involves lymphocytes and lymphocyte-derived mediators, as well as inflammatory cells and various other agents such as complement. These activities are not confined to cytodestructive processes; recent studies demonstrate that the migration characteristics of tumor cells may be modified by immunologically derived substances.

Related Journals of Tumour Immunity

Journal of Tumor Marker Oncology, Rare Tumors, Tumor, Tumor Research, Cancer Case Presentations: The Tumor Board

Cancer Immunoediting

Immunoediting is characterized by changes in the immunogenicity of tumours due to the anti-tumour response of the immune system, resulting in the emergence of immune-resistant variants. It consists of 3 phases- elimination, equilibrium and escape.

Related Journals of Cancer Immunoediting

Journal of the National Cancer Institute. Monographs, Cancer Investigation, Cancer Genetics and Cytogenetics, European Journal of Cancer Prevention, Cancer Journal

Immunotherapeutic agents

Immunotherapeutic agents use or modify immune mechanisms. Use of these agents is rapidly evolving; new classes, new agents, and new uses of current agents are certain to be developed. Immunotherapy is the "treatment of disease by inducing, enhancing, or suppressing an immune response".

Related Journals of Immunotherapeutic agents

Human Vaccines and Immunotherapeutics, Immunotherapy: Open Access, Immunotherapy, International Journal of Immunotherapy, Cancer Immunology and Immunotherapy

Immunogene response

Immunogenicity is the ability of a particular substance, such as an antigen or epitope, to provoke an immune response in the body of a human or animal. In other words, immunogenicity is the ability to induce a humoral and/or cell mediated immune response.

Related Journals of Immunogene response

Immunogenetics, International Journal of Immunogenetics, Experimental and Clinical Immunogenetics, Reviews in Immunogenetics, Immunology and Immunogenetics Insights

Bladder Carcinoma in Situ

The cancerous cells appear to be present and proliferating in an abnormal huge quantity within the line of epithelial cells of urinary bladder is termed as Bladder CIS (Carcinoma in situ). The term CIS is also known as in situ neoplasm where the cancerous cells accumulate as a neoplasm on the outer dermis but fails to penetrate the epithelial wall and doesn’t spread into the inner one.

Related Journals of Bladder Carcinoma in Situ

Clinical Genitourinary Cancer, Breast Cancer Research, Prostate Cancer and Prostatic Diseases, Clinical Colorectal Cancer, Gastric and Breast Cancer

Transitional cell carcinoma (TCC)

The most common type of urinary cancer also known as the creeping tumor arises from the transitional dermis and spreads along the urothelial cellular lining of the organs of urinary system which hails damage to urinary system, kidney, urinary bladder, and accessory organs. The cancerous cells are formed in the renal pelvis and ureter.

Related Journals of Transitional Cell Carcinoma (TCC)

Handbook of Immunohistochemistry and in Situ Hybridization of Human Carcinomas, Clinical Genitourinary Cancer, Breast Cancer Research, Prostate Cancer and Prostatic Diseases, Clinical Colorectal Cancer, Gastric and Breast Cancer


Recently Published Articles

Sertoli-Leydig Cell Tumor of the Ovary in a Postmenopausal Woman
Debora Chantada de la Fuente, Maria de los Angeles Peteiro Cancelo, Laura Juaneda-Magdalena Benavides and Lara Alberta Lista
 
Significance of Morphological and Functional Imaging in Assessment of Residual and Recurrent Disease in Head and Neck Carcinomas
Abhishek Purkayastha
 
Delayed Immune-Related Erythrodermia in a Squamous NSCLC Patient Treated with Nivolumab: A Case Report
Iacono D, Osman GA, Romano MCP, Ricciardi S, Greco S, Signora M, Lombardi A, Pallone G, Pacifici R and Migliorino MR
 
The Effects of Checkpoint Blockade and a CD40 Agonist on Tindependent and T-dependent Antibody Responses in Mice: Implications for Optimization of Vaccination Strategies in Patients Receiving Immunotherapies
Karen M Michel, Ashley Gehrand, Michael A Thompson and Martin Oaks
 
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version